Page last updated: 2024-11-07

17,20,21-trihydroxy-4-pregnen-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

17,20,21-trihydroxy-4-pregnen-3-one: steroid from Micropogonias undulatus during oocyte maturation; RN given for cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID625566
MeSH IDM0147694

Synonyms (5)

Synonym
FT-0665788
17,20,21-trihydroxy-4-pregnen-3-one
17-alpha,20-beta,21-trihydroxypregn-4-en-3-one
17-alpha,20-alpha,21-trihydroxypregn-4-en-3-one
DTXSID60871612

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response experiments with 20 beta-S and 17 alpha,20 beta-dihydroxy-4-pregnen-3-one (17 alpha,20 beta-P) over a range of incubation times yielded similar results for both steroids, suggesting that conversion of 17 alpha,20 beta-P to 20 beta-S is not required for 17 alpha,20 beta-P-induced GVBD."( Induction of maturation of Atlantic croaker oocytes by 17 alpha,20 beta,21-trihydroxy-4-pregnen-3-one in vitro: consideration of some biological and experimental variables.
PatiƱo, R; Thomas, P, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (10.81)18.7374
1990's11 (29.73)18.2507
2000's18 (48.65)29.6817
2010's4 (10.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.63%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (97.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]